person · Reporting owner
Nicacio Leonardo Viana
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc.CRBP · Entity 6261 | Chief Medical Officer | August 16, 2026 | August 17, 2026 |
| Protara Therapeutics, Inc.TARA · Entity 6203 | Chief Medical Officer | January 16, 2026 | January 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corbus Pharmaceuticals Holdings, Inc.
Report date August 16, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 58,333 |
Reported balance
After 2026-08-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-16 · Grant · Acquired 58,333 · Balance 58,333 F1: On August 16, 2026, the Reporting Person was granted 58,333 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth annual anniversary beginning on August 16, 2027. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a prorata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardee's termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service. F2: This amount includes 58,333 unvested RSUs granted on August 16, 2026. |
| Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.09 · Expires 2036-08-16 | Direct | 191,676 |
Reported balance
After 2026-08-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-16 · Grant · Acquired 191,676 · Balance 191,676 F3: This option award was made in accordance with the terms of the issuer's 2026 Inducement Award Plan. 25% of the option vests on August 3, 2027, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on September 3, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 16, 2026, the Reporting Person was granted 58,333 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth annual anniversary beginning on August 16, 2027. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a prorata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardee's termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.
F2: This amount includes 58,333 unvested RSUs granted on August 16, 2026.
F3: This option award was made in accordance with the terms of the issuer's 2026 Inducement Award Plan. 25% of the option vests on August 3, 2027, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on September 3, 2027.
Protara Therapeutics, Inc.
Report date January 16, 2026 · Filed January 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 78,181 |
Reported balance
After 2026-01-16 transaction · row 1
1 source rowRow 1 · 2026-01-16 · Grant · Acquired 26,000 · Balance 78,181 F1: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 16, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.01 · Expires 2036-01-15 | Direct | 158,000 |
Reported balance
After 2026-01-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-16 · Grant · Acquired 158,000 · Balance 158,000 F2: 25% of the shares vest on the one year anniversary of January 16, 2026 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 16, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date.
F2: 25% of the shares vest on the one year anniversary of January 16, 2026 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 16, 2026 Filed Aug 17, 2026 20:30 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock options (right to buy) · Derivative | 191,676 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0001193125-26-354145 · ownership.xml · derivative · entry 2 Nicacio Leonardo Viana · CIK 0002064901 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,676 Underlying: Common Stock · 191,676 shares Expires 2036-08-16 F3 · derivative.exercise_date: This option award was made in accordance with the terms of the issuer's 2026 Inducement Award Plan. 25% of the option vests on August 3, 2027, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on September 3, 2027. Read SEC document |
| August 16, 2026 Filed Aug 17, 2026 20:30 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantCommon Stock, par value $0.0001 per share | 58,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-354145 · ownership.xml · nonDerivative · entry 1 Nicacio Leonardo Viana · CIK 0002064901 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,333 F1 · shares: On August 16, 2026, the Reporting Person was granted 58,333 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth annual anniversary beginning on August 16, 2027. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a prorata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardee's termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service. F2 · balance_after: This amount includes 58,333 unvested RSUs granted on August 16, 2026. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:36 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 158,000 | $0.00 Strike: $5.01 | $0.00 |
DisclosureSEC source: 0001213900-26-006228 · marketforms-71899.xml · derivative · entry 2 Nicacio Leonardo Viana · CIK 0002064901 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,000 Underlying: Common Stock · 158,000 shares Expires 2036-01-15 F2 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 16, 2026 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:36 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-006228 · marketforms-71899.xml · nonDerivative · entry 1 Nicacio Leonardo Viana · CIK 0002064901 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,181 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 16, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $4.17 | $0.00 |
DisclosureSEC source: 0001213900-25-032965 · ownership.xml · derivative · entry 2 Nicacio Leonardo Viana · CIK 0002064901 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-04-14 F2 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of April 15, 2025 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-032965 · ownership.xml · nonDerivative · entry 1 Nicacio Leonardo Viana · CIK 0002064901 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,181 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of April 15, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.